A Rare Case of De Novo CD5+ Diffuse Large B-cell Lymphoma in Leukemic Phase and Positive for CD13

Overview

Journal Hematol Rep

Publisher MDPI

Date 2018 Feb 1

PMID 29383225

Citations 3

Authors

Giovanni Carulli

Eugenio Mario Ciancia

Francesco Caracciolo

Paola Sammuri

Cristiana Domenichini

Maria Immacolata Ferreri

Alessia Di Vita

Virginia Ottaviano

Martina Rousseau

Mario Petrini

Affiliations

Soon will be listed here.

Citing Articles

CD5+ Diffuse Large B-Cell Lymphoma With Leukemic Transformation: A Rare Case With Central Nervous System Involvement, Treated With R-CHOP and Intrathecal Methotrexate/Cytarabine.

Cordova J, Nelson B, Brizendine A, Iqbal F, Venkatesan R Cureus. 2021; 13(6):e15838.

PMID: 34327076 PMC: 8301267. DOI: 10.7759/cureus.15838.

A Clinical Triad with Fatal Implications: Recrudescent Diffuse Large B-cell Non-Hodgkin Lymphoma Presenting in the Leukemic Phase with an Elevated Serum Lactic Acid Level and Dysregulation of the TP53 Tumor Suppressor Gene - A Case Report and....

Hwang C, Hwang D, Aboulafia D Clin Med Insights Blood Disord. 2021; 14:2634853521994094.

PMID: 33679144 PMC: 7897840. DOI: 10.1177/2634853521994094.

Diffuse large B-cell lymphoma in blood and bone marrow: a rare presentation of leukemic phase at diagnosis.

Suresh P, Basavaiah S, Goel M, Dsouza S, Rai S Hematol Transfus Cell Ther. 2019; 42(2):180-183.

PMID: 31439514 PMC: 7248510. DOI: 10.1016/j.htct.2019.04.005.

References

Muringampurath-John D, Jaye D, Flowers C, Saxe D, Chen Z, Lechowicz M . Characteristics and outcomes of diffuse large B-cell lymphoma presenting in leukaemic phase. Br J Haematol. 2012; 158(5):608-14. DOI: 10.1111/j.1365-2141.2012.09209.x. View

Bovio I, Allan R . The expression of myeloid antigens CD13 and/or CD33 is a marker of ALK+ anaplastic large cell lymphomas. Am J Clin Pathol. 2008; 130(4):628-34. DOI: 10.1309/PLN1NA4QB2PC1CMQ. View

Wang K, Zhang J, Dong C, Ren F, Wu R, Guo J . [De novo CD5- positive diffuse large B- cell lymphoma in leukemic phase with highly chromosome complex aberrations and splenic infarction: a case report and literatures review]. Zhonghua Xue Ye Xue Za Zhi. 2015; 36(10):887. PMC: 7364951. DOI: 10.3760/cma.j.issn.0253-2727.2015.10.020. View

Wickstrom M, Larsson R, Nygren P, Gullbo J . Aminopeptidase N (CD13) as a target for cancer chemotherapy. Cancer Sci. 2011; 102(3):501-8. PMC: 7188354. DOI: 10.1111/j.1349-7006.2010.01826.x. View

Alinari L, Gru A, Quinion C, Huang Y, Lozanski A, Lozanski G . De novo CD5+ diffuse large B-cell lymphoma: Adverse outcomes with and without stem cell transplantation in a large, multicenter, rituximab treated cohort. Am J Hematol. 2016; 91(4):395-9. PMC: 4877689. DOI: 10.1002/ajh.24299. View

Saxena A, Rai A, Raina V, Seth T, Mitra D . Expression of CD13/aminopeptidase N in precursor B-cell leukemia: role in growth regulation of B cells. Cancer Immunol Immunother. 2009; 59(1):125-35. PMC: 11030730. DOI: 10.1007/s00262-009-0731-6. View

Yamaguchi M, Nakamura N, Suzuki R, Kagami Y, Okamoto M, Ichinohasama R . De novo CD5+ diffuse large B-cell lymphoma: results of a detailed clinicopathological review in 120 patients. Haematologica. 2008; 93(8):1195-202. DOI: 10.3324/haematol.12810. View

Hsiao H, Wang H, Tsai Y, Hsiao C, Cho S, Liu Y . Leukemic Phase of CD5+ Diffuse Large B-Cell Lymphoma. Turk J Haematol. 2017; 35(3):197-198. PMC: 6110439. DOI: 10.4274/tjh.2016.0447. View

Shim H, Ha J, Lee H, Sohn J, Kim H, Eom H . Expression of myeloid antigen in neoplastic plasma cells is related to adverse prognosis in patients with multiple myeloma. Biomed Res Int. 2014; 2014:893243. PMC: 4065753. DOI: 10.1155/2014/893243. View

10.

Suggs J, Cruse J, Lewis R . Aberrant myeloid marker expression in precursor B-cell and T-cell leukemias. Exp Mol Pathol. 2007; 83(3):471-3. DOI: 10.1016/j.yexmp.2007.08.012. View

11.

Jain P, Fayad L, Rosenwald A, Young K, OBrien S . Recent advances in de novo CD5+ diffuse large B cell lymphoma. Am J Hematol. 2013; 88(9):798-802. DOI: 10.1002/ajh.23467. View

12.

van Dongen J, Langerak A, Bruggemann M, Evans P, Hummel M, Lavender F . Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia. 2003; 17(12):2257-317. DOI: 10.1038/sj.leu.2403202. View

13.

Yoshida K, Kayano H, Akiba M, Kishimoto K, Takahashi N, Sugahara Y . [De novo CD5-positive diffuse large B-cell lymphoma with leukemic dissemination diagnosed by immunohistochemical examinations of bone marrow clot sections]. Rinsho Ketsueki. 2002; 43(10):943-8. View

14.

Saito M, Kumagai M, Okazaki T, Nakazawa S, Shapiro L, Look A . Stromal cell-mediated transcriptional regulation of the CD13/aminopeptidase N gene in leukemic cells. Leukemia. 1995; 9(9):1508-16. View

15.

Kampalath B, Barcos M, Stewart C . Phenotypic heterogeneity of B cells in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. Am J Clin Pathol. 2003; 119(6):824-32. DOI: 10.1309/4AGU-T3LK-EURD-7T7K. View

16.

Riemann D, Kehlen A, Langner J . CD13--not just a marker in leukemia typing. Immunol Today. 1999; 20(2):83-8. PMC: 7141563. DOI: 10.1016/s0167-5699(98)01398-x. View

17.

Dunphy C, GARDNER L, Manes J, Bee C, Taysi K . CD30+ anaplastic large-cell lymphoma with aberrant expression of CD13: case report and review of the literature. J Clin Lab Anal. 2001; 14(6):299-304. PMC: 6807975. View

18.

Carbone A, Gloghini A, Volpe R, Pinto A . KP1 (CD68)-positive large cell lymphomas: a histopathologic and immunophenotypic characterization of 12 cases. Hum Pathol. 1993; 24(8):886-96. DOI: 10.1016/0046-8177(93)90139-8. View

19.

Chuang W, Chang H, Chang G, Wang T, Chang Y, Wang T . Pleomorphic mantle cell lymphoma morphologically mimicking diffuse large B cell lymphoma: common cyclin D1 negativity and a simple immunohistochemical algorithm to avoid the diagnostic pitfall. Histopathology. 2016; 70(6):986-999. DOI: 10.1111/his.13161. View

20.

Shipp M, Look A . Hematopoietic differentiation antigens that are membrane-associated enzymes: cutting is the key!. Blood. 1993; 82(4):1052-70. View